Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.43

-0.7%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (7774)	9/26/1997 4:55:00 PM
From: Henry Niman	of 32384

Here's another study showing increased risk of breast cancer for women on hormone replacement therapy for 10 or more years. Interestingly, the risk was higher when the hormone was opposed by Progesterone: Long-Term Hormone Replacement Increases Breast Cancer Risk WESTPORT, Sep 26 (Reuters) - Women who use hormone replacement therapy, particularly with adjunctive progestins, for more than 10 years may be at a "moderately increased" risk of breast cancer, according to the results of a nested case-control study conducted in Sweden. A team of researchers at the University of Uppsala led by Dr. Ingemar Persson identified 435 cases of incident breast cancer patients over 5 years among a cohort of some 36,000 women who participated in mammography screening. The cases were matched to 1,740 controls. The use of hormone replacement therapy (HRT) of any type "...for more than 10 years was linked to a doubled risk of breast cancer." The risk was particularly elevated in women who used estrogen-progestin combinations compared with those using estrogens alone, with the odds ratios for more than 10 years of use being 2.4 and 1.3, respectively, compared with nonusers of HRT. Dr. Persson and colleagues point out in the September 4 issue of the International Journal of Cancer that these findings should be taken into account "[w]hen assessing the overall risks and benefits of HRT." Int J Cancer 1997;72:758-761.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next